 efficacy azathioprine relapsing-remitting multiple sclerosis patients relapsing-remitting multiple sclerosis azathioprine AZA mg/kg daily placebo double-masked therapeutic trial Analysis data predetermined primary outcome measures significant difference AZA observed mean exacerbation rate years therapy time deterioration Ambulation Index Kurtzke Expanded Disability Status Scale score study modest therapeutic benefit azathioprine investigators